Protein kinase C ϵ stabilizes β-catenin and regulates its subcellular localization in podocytes

J Biol Chem. 2017 Jul 21;292(29):12100-12110. doi: 10.1074/jbc.M117.775700. Epub 2017 May 24.

Abstract

Kidney disease has been linked to dysregulated signaling via PKC in kidney cells such as podocytes. PKCα is a conventional isoform of PKC and a well-known binding partner of β-catenin, which promotes its degradation. β-Catenin is the main effector of the canonical Wnt pathway and is critical in cell adhesion. However, whether other PKC isoforms interact with β-catenin has not been studied systematically. Here we demonstrate that PKCϵ-deficient mice, which develop proteinuria and glomerulosclerosis, display lower β-catenin expression compared with PKC wild-type mice, consistent with an altered phenotype of podocytes in culture. Remarkably, β-catenin showed a reversed subcellular localization pattern: Although β-catenin exhibited a perinuclear pattern in undifferentiated wild-type cells, it predominantly localized to the nucleus in PKCϵ knockout cells. Phorbol 12-myristate 13-acetate stimulation of both cell types revealed that PKCϵ positively regulates β-catenin expression and stabilization in a glycogen synthase kinase 3β-independent manner. Further, β-catenin overexpression in PKCϵ-deficient podocytes could restore the wild-type phenotype, similar to rescue with a PKCϵ construct. This effect was mediated by up-regulation of P-cadherin and the β-catenin downstream target fascin1. Zebrafish studies indicated three PKCϵ-specific phosphorylation sites in β-catenin that are required for full β-catenin function. Co-immunoprecipitation and pulldown assays confirmed PKCϵ and β-catenin as binding partners and revealed that ablation of the three PKCϵ phosphorylation sites weakens their interaction. In summary, we identified a novel pathway for regulation of β-catenin levels and define PKCϵ as an important β-catenin interaction partner and signaling opponent of other PKC isoforms in podocytes.

Keywords: PKC; Wnt pathway; cadherin; cytoskeleton; glycogen synthase kinase 3 (GSK-3); kidney; podocytes; β-catenin.

Publication types

  • Comparative Study
  • Validation Study

MeSH terms

  • Active Transport, Cell Nucleus / drug effects
  • Amino Acid Substitution
  • Animals
  • Biological Assay
  • Carcinogens / toxicity
  • Cell Line, Transformed
  • Gene Expression Regulation / drug effects
  • Glycogen Synthase Kinase 3 beta / metabolism
  • HEK293 Cells
  • Humans
  • Mice, Knockout
  • Mutagenesis, Site-Directed
  • Mutation
  • Phosphorylation / drug effects
  • Podocytes / cytology
  • Podocytes / drug effects
  • Podocytes / metabolism*
  • Protein Kinase C-epsilon / antagonists & inhibitors
  • Protein Kinase C-epsilon / genetics
  • Protein Kinase C-epsilon / metabolism*
  • Protein Processing, Post-Translational* / drug effects
  • Protein Stability / drug effects
  • Recombinant Proteins / chemistry
  • Recombinant Proteins / metabolism
  • Tetradecanoylphorbol Acetate / analogs & derivatives
  • Tetradecanoylphorbol Acetate / toxicity
  • Tissue Culture Techniques
  • beta Catenin / antagonists & inhibitors
  • beta Catenin / chemistry
  • beta Catenin / genetics
  • beta Catenin / metabolism*

Substances

  • CTNNB1 protein, mouse
  • Carcinogens
  • Recombinant Proteins
  • beta Catenin
  • phorbolol myristate acetate
  • Prkce protein, mouse
  • Glycogen Synthase Kinase 3 beta
  • Protein Kinase C-epsilon
  • Tetradecanoylphorbol Acetate